Zhitong Finance App News, Guangshengtang (300436.SZ) announced that Fujian Guangsheng Zhonglin Biotechnology Co., Ltd., the company's innovative pharmaceutical holding subsidiary, is carrying out a randomized, double-blind, placebo-controlled clinical trial (GST-peak-triple) to evaluate the safety and efficacy of the trifecta full oral half-year treatment plan (GST-HG141+GST-HG131+ NAS nucleoside (acid)) in patients with chronic hepatitis B virus (GST-Peak-Triple). A total of 176 participants were enrolled in the group. .
Clinical studies have shown that GST-HG131 has a significant inhibitory effect on HBsAg, the surface antigen of the hepatitis B virus. GST-HG141 strongly inhibits HBVDNA and pgRNA, and shows potential depletion effects on cccDNA. The two are expected to complement each other in terms of antiviral mechanisms. Based on this, the peak-triple clinical study of GST-HG131 combined with GST-HG141 aims to evaluate the functional cure status of patients with chronic hepatitis B with a limited course of treatment with a limited course of treatment based on nucleoside (acid) analogs, with a view to providing more effective full oral treatment options for hepatitis B patients, and is committed to achieving the company's Hepatitis B peak plan. The joint program was included in the “Pilot Project for Optimizing Clinical Trial Evaluation and Approval of Innovative Drugs” in March 2025, and its related sequential combination treatment plan was selected for the “Prevention and Control of Emerging Outbreaks and Major Infectious Diseases” National Science and Technology Major Project for Clinical Treatment of Hepatitis B in January 2026; both GST-HG131 and GST-HG141 were included in the list of breakthrough treatment varieties.